Scholarlink

Purpose <p>Whether tumor size affects the survival of patients undergoing liver resection (LR) for a single hepatocellular carcinoma (HCC) without microscopic vascular invasion (MVI), i.e., pathological T1N0M0, is controversial.</p> Methods <p>We enrolled 626 patients with HCC of pathological stage T1N0M0 of the 7th edition of American Joint Committee on Cancer staging who underwent LR between 2011 and 2021 at our institution. The overall survival (OS) and recurrence-free survival (RFS) of patients with T1N0M0 HCC &gt; 5.0&#xa0;cm and those with T1N0M0 HCC ≤ 5.0&#xa0;cm was compared using the Kaplan–Meier estimator and log-rank test both before and after propensity score matching (PSM).</p> Results <p>Ninety-two (14.7%) patients had T1N0M0 HCC &gt; 5.0&#xa0;cm. The proportion of patients with cirrhosis was lower in the T1N0M0 HCC &gt; 5.0&#xa0;cm group than in the T1N0M0 HCC ≤ 5.0&#xa0;cm group (16.3 vs 41.2%, <i>p</i> &lt; 0.001). Five-year OS did not differ significantly between the two groups before PSM (82 vs 84%, <i>p</i> = 0.857) or after PSM (84 vs 94%, <i>p</i> = 0.678). Five-year RFS did not differ significantly between the two groups before PSM (63 vs. 66%, <i>p</i> = 0.778) or after PSM (65 vs. 65%, <i>p</i> = 0.371).</p> Conclusion <p>Tumor size did not affect the survival outcomes of patients undergoing LR for T1N0M0 HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumor Size Does Not Affect Survival Outcomes of Patients Undergoing Resection for a Single Hepatocellular Carcinoma Without Microscopic Vascular Invasion in the Modern Era of Antiviral Therapy

  • 期刊论文

  • 发表日期：

    2025年7月24日

查看全文
  • Yi-Hao Yen,
  • Fang-Ying Kuo,
  • Hock-Liew Eng,
  • Yueh-Wei Liu,
  • Chee-Chien Yong,
  • Chih-Chi Wang,
  • Wei-Feng Li,
  • Chih-Yun Lin

摘要

Purpose

Whether tumor size affects the survival of patients undergoing liver resection (LR) for a single hepatocellular carcinoma (HCC) without microscopic vascular invasion (MVI), i.e., pathological T1N0M0, is controversial.

Methods

We enrolled 626 patients with HCC of pathological stage T1N0M0 of the 7th edition of American Joint Committee on Cancer staging who underwent LR between 2011 and 2021 at our institution. The overall survival (OS) and recurrence-free survival (RFS) of patients with T1N0M0 HCC > 5.0 cm and those with T1N0M0 HCC ≤ 5.0 cm was compared using the Kaplan–Meier estimator and log-rank test both before and after propensity score matching (PSM).

Results

Ninety-two (14.7%) patients had T1N0M0 HCC > 5.0 cm. The proportion of patients with cirrhosis was lower in the T1N0M0 HCC > 5.0 cm group than in the T1N0M0 HCC ≤ 5.0 cm group (16.3 vs 41.2%, p < 0.001). Five-year OS did not differ significantly between the two groups before PSM (82 vs 84%, p = 0.857) or after PSM (84 vs 94%, p = 0.678). Five-year RFS did not differ significantly between the two groups before PSM (63 vs. 66%, p = 0.778) or after PSM (65 vs. 65%, p = 0.371).

Conclusion

Tumor size did not affect the survival outcomes of patients undergoing LR for T1N0M0 HCC.